{"id":"evaluation-of-vaccines-against-flu","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site soreness or erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Low-grade fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Flu vaccines contain inactivated or attenuated influenza virus antigens that trigger both humoral (antibody) and cell-mediated immune responses. This allows the body to recognize and rapidly neutralize circulating influenza viruses upon exposure, reducing infection rates and disease severity. Multiple vaccine formulations exist (trivalent, quadrivalent, high-dose, adjuvanted) targeting different age groups and risk populations.","oneSentence":"Flu vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection and severe disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:52.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"},{"name":"Influenza prevention in high-risk populations (elderly, immunocompromised, healthcare workers)"}]},"trialDetails":[{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT05446740","phase":"PHASE1","title":"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-09","conditions":"Influenza, Human","enrollment":324},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT06179446","phase":"PHASE1","title":"A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-13","conditions":"Grippe, Influenza, Vaccines","enrollment":157},{"nctId":"NCT06382311","phase":"PHASE1, PHASE2","title":"A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-18","conditions":"Influenza, Human","enrollment":991},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT06907511","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-04-17","conditions":"Pandemic Influenza Immunization, Healthy Volunteers","enrollment":720},{"nctId":"NCT06436703","phase":"PHASE2","title":"A Study About Modified RNA Vaccines Against Influenza in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":1202},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT01065285","phase":"PHASE4","title":"Vaccination Against Influenza in Autoimmune Diseases","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-10","conditions":"Autoimmune Diseases","enrollment":234},{"nctId":"NCT07121192","phase":"PHASE2","title":"A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-25","conditions":"Influenza, Human","enrollment":776},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT06683352","phase":"PHASE1, PHASE2","title":"A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2024-11-11","conditions":"Influenza,Human, COVID-19","enrollment":1353},{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT05823974","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-04-27","conditions":"Influenza, Human","enrollment":1275},{"nctId":"NCT05540522","phase":"PHASE3","title":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-12","conditions":"Influenza, Human","enrollment":45789},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05788237","phase":"PHASE1","title":"A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-09","conditions":"Healthy","enrollment":508},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05559476","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-20","conditions":"Respiratory Syncytial Virus Infections","enrollment":1029},{"nctId":"NCT04841577","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-27","conditions":"Respiratory Syncytial Virus Infections","enrollment":976},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05052697","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-13","conditions":"Influenza, Human","enrollment":1158},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279},{"nctId":"NCT01394640","phase":"","title":"Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients","status":"COMPLETED","sponsor":"Paolo Corradini","startDate":"2009-10","conditions":"Lymphoma, Multiple Myeloma, Myeloproliferative Disease","enrollment":124},{"nctId":"NCT05060887","phase":"PHASE2","title":"Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2021-11-15","conditions":"Influenza","enrollment":239},{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT01693380","phase":"PHASE4","title":"Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2009-05","conditions":"Influenza, Acute Respiratory Infection","enrollment":1742},{"nctId":"NCT04001504","phase":"PHASE3","title":"Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-07-19","conditions":"Acute Coronary Syndrome","enrollment":1801},{"nctId":"NCT03328325","phase":"PHASE4","title":"Age and Response to Flu Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-12-14","conditions":"Influenza, Influenza Immunisation","enrollment":152},{"nctId":"NCT04806529","phase":"PHASE2, PHASE3","title":"An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older","status":"WITHDRAWN","sponsor":"Seqirus","startDate":"2020-12-15","conditions":"Influenza","enrollment":""},{"nctId":"NCT04034290","phase":"PHASE2","title":"A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac","status":"COMPLETED","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2019-10-18","conditions":"Healthy Volunteers","enrollment":224},{"nctId":"NCT04086628","phase":"","title":"Influenza Vaccine in Children With Asthma","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2019-11-04","conditions":"Asthma in Children, Influenza Vaccine, Immunization Coverage","enrollment":500},{"nctId":"NCT01155037","phase":"PHASE2","title":"Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2010-03","conditions":"HIV Infection","enrollment":450},{"nctId":"NCT00992212","phase":"PHASE2","title":"Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza Disease","enrollment":418},{"nctId":"NCT01160237","phase":"PHASE3","title":"Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Influenza","enrollment":7},{"nctId":"NCT01044095","phase":"NA","title":"Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2009-11","conditions":"Influenza","enrollment":26},{"nctId":"NCT01032395","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-03","conditions":"H1N1 Influenza Virus, Chronic Pulmonary Disease, Chronic Heart Disease","enrollment":342},{"nctId":"NCT01032408","phase":"PHASE3","title":"Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-04","conditions":"H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":154},{"nctId":"NCT01457027","phase":"PHASE4","title":"A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-10","conditions":"Influenza","enrollment":52},{"nctId":"NCT01111968","phase":"PHASE1","title":"Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2010-01","conditions":"Influenza","enrollment":266},{"nctId":"NCT01031719","phase":"PHASE3","title":"Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors","status":"COMPLETED","sponsor":"Chiltern Pesquisa Clinica Ltda","startDate":"2010-08","conditions":"H1N1 Influenza Virus, Invasive Solid Tumors","enrollment":59},{"nctId":"NCT01247415","phase":"","title":"Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine","status":"UNKNOWN","sponsor":"PHAC/CIHR Influenza Research Network","startDate":"2011-01","conditions":"Anaphylaxis, Allergy, Oculorespiratory Syndrome","enrollment":138},{"nctId":"NCT01577316","phase":"PHASE2, PHASE3","title":"Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women","status":"UNKNOWN","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2012-04","conditions":"Pregnancy, Investigation or Care in A Nonpregnant Woman","enrollment":240},{"nctId":"NCT00989274","phase":"PHASE2","title":"Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1","status":"WITHDRAWN","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2010-06","conditions":"Influenza","enrollment":""},{"nctId":"NCT00539864","phase":"PHASE3","title":"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2007-09","conditions":"Influenza","enrollment":602},{"nctId":"NCT01039623","phase":"NA","title":"Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2010-01","conditions":"Healthy","enrollment":200},{"nctId":"NCT00216242","phase":"PHASE3","title":"Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.","status":"UNKNOWN","sponsor":"ID Biomedical Corporation, Quebec","startDate":"2005-09","conditions":"Influenza","enrollment":7400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Evaluation of vaccines against flu in auto-imune diseases"],"phase":"marketed","status":"active","brandName":"Evaluation of vaccines against flu","genericName":"Evaluation of vaccines against flu","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Biologic","firstApprovalDate":"","aiSummary":"Flu vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection and severe disease. Used for Seasonal influenza prevention in adults and children, Influenza prevention in high-risk populations (elderly, immunocompromised, healthcare workers).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}